FDA Approves Olutasidenib (Rezlidhia) for Certain Patients With AML
The drug has been approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.
United States Jorges Cortes Georgia Cancer Center Drug Administration Abbott Realtime Acute Leukemia
Source: medscape.com